XPH — SPDR(R) S&P(R) Pharmaceuticals ETF
Data updated: 2026-05-28
XPH — SPDR(R) S&P(R) Pharmaceuticals ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $307.87M AUM · 0.35% expense ratio · 24.1% 1-yr return. From SEC regulatory filings.
XPH Fund Overview
XPH — SPDR(R) S&P(R) Pharmaceuticals ETF is a US ETF managed by SPDR Series Trust, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: SPDR Series Trust
- Category: United States Health Care Equity
- Assets under management: $307.87M
- 1-year return: 24.1%
- Ticker: XPH
- SEC CIK: 0001064642
- SEC series ID: S000012321
- Share class ID: C000033537
XPH Holdings
Top 10 holdings of SPDR(R) S&P(R) Pharmaceuticals ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| State Street Global Advisors | 7.93% |
| Enliven Therapeutics Inc | 2.45% |
| Corcept Therapeutics Inc | 2.29% |
| Terns Pharmaceuticals Inc | 2.16% |
| Perrigo Co PLC | 2.10% |
| Axsome Therapeutics Inc | 2.03% |
| Innoviva Inc | 1.99% |
| Merck & Co Inc | 1.98% |
| Pfizer Inc | 1.97% |
| Royalty Pharma PLC | 1.97% |
XPH Portfolio Allocation
Asset-class allocation of SPDR(R) S&P(R) Pharmaceuticals ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.9% |
| Cash & Equivalents | 8.0% |
XPH Performance
Total returns for XPH (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -3.6% |
| 1 year | 24.1% |
| 3 years (annualised) | 11.0% |
| 5 years (annualised) | 2.8% |
XPH Risk Information
Risk metrics for XPH, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 20.7%
XPH Costs and Fees
XPH costs about $35 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.35%
- Gross expense ratio: 0.35%
- Portfolio turnover: 45%
- Brokerage commissions: 1.55 bps of average net assets (SEC N-CEN)
XPH Cashflows
Over the 12 months to 2026-03, SPDR(R) S&P(R) Pharmaceuticals ETF had net inflows of $111.37M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | −$31.15K |
| 2026-02 | $28.22M |
| 2026-01 | $61.59M |
| 2025-12 | $15.46M |
| 2025-11 | $5.18M |
| 2025-10 | $2.46M |
XPH Debt Constituents
No individual debt constituents are reported in SPDR(R) S&P(R) Pharmaceuticals ETF's latest SEC N-PORT filing.
XPH Prospectus and SEC Filings
Official SPDR(R) S&P(R) Pharmaceuticals ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.